Saturday, July 5, 2025 7/5/2025

Genetic Basis of Lifespan and Healthspan Extension by ACE Inhibition in Drosophila

Award Number: R01AG073181
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/15/2022
PERIOD OF PERFORMANCE END DATE: 04/30/2027

Group Awards By:

View Award Description

Genetic Basis of Lifespan and Healthspan Extension by ACE Inhibition in Drosophila - PROJECT SUMMARY Studies across a broad range of species have established a common set of evolutionarily conserved hallmarks of aging, including age-related decline in mobility and mitochondrial failure. This evidence points to the potential for pharmacological intervention to improve healthy aging and extend longevity. Pharmacological blockade of the Renin Angiotensin System (RAS) by inhibition of the angiotensin-converting enzyme (ACE) is an effective therapy in improving age-related impairment of physical function and is a potential strategy to slow human aging. The beneficial effect of ACE ihibition in reducing age-associated damage of tissues, such as the skeletal muscle, may be attributed in part by the drug’s capacity to preserve mitochondrial function. However, improvement in physical performance in response to RAS blockade varies widely in human studies, potentially due to genetic variation among individuals. Research in this area has been slowed by lack of understanding of the biology that connects aging, genetics, and response to drug treatment and because of the shortage of appropriate animal models for biological and intervention studies. To tackle this issue, we propose to leverage the evolutionary conservation of ACE across species to determine the genetic basis for the anti-aging effect of the ACEi Lisinopril in the invertebrate model D. melanogaster. The proposed research builds on a powerful genomics resource, the Drosophila Genetic Reference Panel (DGRP), which consists of genetically distinct lines of flies derived from a natural population. Our preliminary studies using three genetically diverse DGRP lines revealed that treatment with Lisinopril extends lifespan and improves age-specific walking in D. melanogaster, but it does so in a genotype-specific manner. Our data also suggest that genotype-specific responses to Lisinopril may act, in part, through variation in the degree to which mitochondrial function is affected by the drug treatment. To address this hypothesis, we propose to use genome-wide association mapping in 400 new DGRP lines to first identify variants, genes and genetic pathways that respond to ACEi to ameliorate age-related decline in locomotor activity and extend lifespan (Aim 1). Functional genetic studies using RNA interference (RNAi) of candidate genes are then proposed to validate the effects of ACEi on lifespan and healthspan and to test whether these effects are mediated via changes in mitochondrial function in skeletal muscle (Aim 2). Finally, we propose to evaluate the genome wide effects of ACEi on gene expression and the metabolome for genes for which RNAi in thoracic muscle extends lifespan and/or healthspan in order to gain insight into the mechanism(s) by which ACEi modulates lifespan and healthspan (Aim 3). Completion of the proposed studies will identify genetic and metabolic pathways that regulate the ACEi-mediated improvement in physical performance in older individuals.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $475,402 )
2025	2025	CLEMSON UNIVERSITY	201 SIKES HALL	CLEMSON	SC	29634	PICKENS	USA	Aging Research	000	4	4/30/2025	NON-COMPETING CONTINUATION	$436,595
2025	2025	CLEMSON UNIVERSITY	201 SIKES HALL	CLEMSON	SC	29634	PICKENS	USA	Aging Research	001	4	6/20/2025	NON-COMPETING CONTINUATION	$38,807
														Subtotal = $475,402

Issue Date FY: 2024 ( Subtotal = $485,105 )
2024	2024	CLEMSON UNIVERSITY	201 SIKES HALL	CLEMSON	SC	29634	PICKENS	USA	Aging Research	000	3	6/5/2024	NON-COMPETING CONTINUATION	$485,105
														Subtotal = $485,105

Issue Date FY: 2023 ( Subtotal = $489,689 )
2023	2023	CLEMSON UNIVERSITY	201 SIKES HALL	CLEMSON	SC	29634	PICKENS	USA	Aging Research	000	2	7/28/2023	NON-COMPETING CONTINUATION	$485,105
2023	2022	CLEMSON UNIVERSITY	201 SIKES HALL	CLEMSON	SC	29634	PICKENS	USA	Aging Research	001	1	8/9/2023	NEW	$4,584
														Subtotal = $489,689

Issue Date FY: 2022 ( Subtotal = $498,230 )
2022	2022	CLEMSON UNIVERSITY	201 SIKES HALL	CLEMSON	SC	29634	PICKENS	USA	Aging Research	000	1	8/10/2022	NEW	$498,230
														Subtotal = $498,230

Grand Total All Awards = $1,948,426

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Genetic Basis of Lifespan and Healthspan Extension by ACE Inhibition in Drosophila

Award Number: R01AG073181

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/15/2022

PERIOD OF PERFORMANCE END DATE: 04/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer